VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. Farbice André MD, PhD, from the Institut Gustave Roussy in Villejuif, France, discussed the scope for bridging the gap between new genomic technologies and their application in the real world with Oncology Times reporter Sarah Maxwell.
You may also like...
Genomic-led AML Clinical Decision Making Within Seven Days 31 Dec, 2019 Audio Journal of Oncology Volume 16 Number 8 15 Apr, 2008 Young Women with HER2+ Early Breast Cancer Better with Mastectomy 24 Aug, 2016 Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia 10 Dec, 2007
- Previous story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Next story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014